A Phase 3, Randomized, Double-Blind, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and a Second CFTR Alle
A study for patients with Cystic Fibrosis using study drug VX-661
Sponsor: Vertex Pharmaceuticals Incorporated
Enrolling: Male and Female Patients
IRB Number: AAAQ8846
U.S. Govt. ID: NCT02412111
Contact: Emily DiMango: 212-305-0631 / ead3@cumc.columbia.edu
Additional Study Information: This study is being done to learn more about the safety and effects of the combination of VX-661 and ivacaftor in subjects with Cystic Fibrosis (CF).
This study is closed
Emily DiMango, MD
Do You Qualify?
Have you or your child been diagnosed with Cystic Fibrosis (CF)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Emily DiMango